Shares of Flexion Therapeutics Inc (NASDAQ:FLXN) traded down 0% on Tuesday . The company traded as low as $25.01 and last traded at $25.03. 813,194 shares changed hands during trading, an increase of 26% from the average session volume of 646,934 shares. The stock had previously closed at $25.03.

A number of analysts have weighed in on the company. Zacks Investment Research upgraded Flexion Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, October 26th. Northland Securities reiterated a “buy” rating and set a $40.00 price objective on shares of Flexion Therapeutics in a report on Friday, November 10th. Wells Fargo & Co set a $39.00 price objective on Flexion Therapeutics and gave the company a “buy” rating in a report on Friday, October 6th. Janney Montgomery Scott increased their price objective on Flexion Therapeutics to $570.00 and gave the company a “fair value” rating in a report on Tuesday, October 10th. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $37.00 price objective (up previously from $35.00) on shares of Flexion Therapeutics in a report on Monday, October 9th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $106.25.

The company has a debt-to-equity ratio of 0.87, a quick ratio of 12.93 and a current ratio of 12.93. The firm has a market cap of $939.65, a price-to-earnings ratio of -7.11 and a beta of 1.14.

Flexion Therapeutics (NASDAQ:FLXN) last released its earnings results on Monday, November 6th. The specialty pharmaceutical company reported ($1.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.98) by ($0.09). equities research analysts predict that Flexion Therapeutics Inc will post -3.84 earnings per share for the current year.

In other news, insider Neil Bodick bought 2,700 shares of the business’s stock in a transaction that occurred on Tuesday, November 21st. The shares were purchased at an average cost of $24.49 per share, with a total value of $66,123.00. Following the transaction, the insider now directly owns 64,605 shares in the company, valued at $1,582,176.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Michael D. Clayman bought 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 8th. The stock was purchased at an average cost of $23.60 per share, for a total transaction of $118,000.00. Following the completion of the transaction, the insider now owns 35,395 shares in the company, valued at $835,322. The disclosure for this purchase can be found here. 15.98% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Berson & Corrado Investment Advisors LLC acquired a new position in shares of Flexion Therapeutics in the 4th quarter valued at $324,000. Highbridge Capital Management LLC increased its position in shares of Flexion Therapeutics by 408.2% in the 3rd quarter. Highbridge Capital Management LLC now owns 50,823 shares of the specialty pharmaceutical company’s stock valued at $1,229,000 after acquiring an additional 40,823 shares during the period. Gagnon Securities LLC acquired a new position in shares of Flexion Therapeutics in the 3rd quarter valued at $3,490,000. Uniplan Investment Counsel Inc. acquired a new position in shares of Flexion Therapeutics in the 3rd quarter valued at $2,996,000. Finally, Schwab Charles Investment Management Inc. increased its position in shares of Flexion Therapeutics by 6.3% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 107,550 shares of the specialty pharmaceutical company’s stock valued at $2,601,000 after acquiring an additional 6,336 shares during the period. 72.78% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: This story was first posted by Daily Political and is the property of of Daily Political. If you are accessing this story on another publication, it was copied illegally and reposted in violation of international copyright laws. The legal version of this story can be viewed at https://www.dailypolitical.com/2018/01/16/flexion-therapeutics-flxn-stock-price-down-0.html.

About Flexion Therapeutics

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.